checkAd
    Startseite > Aktien > Vaccitech > Nachrichten
    Vaccitech Aktie
    2,4299
     
    USD
    +9,21 %
    +0,2049 USD
    Letzter Kurs 02:00:00 UTP Consolidated
    2,3800
     
    USD
    200 STK
    Geldkurs 16.05.24
    2,4300
     
    USD
    300 STK
    Briefkurs 16.05.24
    ISIN: US91864C1071 · WKN: A3CN5Q · SYM: BRNS · Großbritannien

    Neueste Nachrichten

    Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
    13.05.24 · globenewswire · Vaccitech
    Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
    01.05.24 · globenewswire · Vaccitech
    Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
    18.04.24 · globenewswire · Vaccitech
    Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
    20.03.24 · globenewswire · Vaccitech
    Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
    05.01.24 · globenewswire · Vaccitech
    New partnership aims to advance vaccine against MERS coronavirus
    21.12.23 · globenewswire · Vaccitech
    Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
    09.11.23 · globenewswire · Vaccitech
    Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
    09.11.23 · globenewswire · Vaccitech
    Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
    06.11.23 · globenewswire · Vaccitech
    Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
    13.09.23 · globenewswire · Vaccitech
    Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
    10.08.23 · globenewswire · Vaccitech
    Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
    21.06.23 · globenewswire · Vaccitech